{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T10:08:04Z","timestamp":1794737284821,"version":"4.9.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82273347"],"award-info":[{"award-number":["No. 82273347"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinical Research Foundation of Central High-level Hospital","award":["No. 2023HQ6"],"award-info":[{"award-number":["No. 2023HQ6"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-025-01211-1","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T03:14:41Z","timestamp":1764731681000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Disitamab vedotin (RC48-ADC) combined with immunotherapy as neoadjuvant therapy for localized muscle-invasive bladder cancer: a multicenter real-world study"],"prefix":"10.1038","volume":"10","author":[{"given":"Xuanjun","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuoyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yechi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yicong","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuke","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiwei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhisong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqing","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuijian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"1211_CR1","doi-asserted-by":"publisher","first-page":"e076743","DOI":"10.1136\/bmj-2023-076743","volume":"384","author":"A Lopez-Beltran","year":"2024","unstructured":"Lopez-Beltran, A., Cookson, M. S., Guercio, B. J. & Cheng, L. Advances in diagnosis and treatment of bladder cancer. BMJ 384, e076743 (2024).","journal-title":"BMJ"},{"key":"1211_CR2","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/NEJMoa022148","volume":"349","author":"HB Grossman","year":"2003","unstructured":"Grossman, H. B. et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349, 859\u2013866 (2003).","journal-title":"N. Engl. J. Med."},{"key":"1211_CR3","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","volume":"29","author":"G Griffiths","year":"2011","unstructured":"Griffiths, G., Hall, R., Sylvester, R., Raghavan, D. & Parmar, M. K. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J. Clin. Oncol. 29, 2171\u20132177 (2011).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR4","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","volume":"391","author":"T Powles","year":"2024","unstructured":"Powles, T. et al. Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer. N. Engl. J. Med. 391, 1773\u20131786 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1211_CR5","first-page":"404","volume":"70","author":"VG Patel","year":"2020","unstructured":"Patel, V. G., Oh, W. K. & Galsky, M. D. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J. Clin. 70, 404\u2013423 (2020).","journal-title":"CA Cancer J. Clin."},{"key":"1211_CR6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41585-020-00404-6","volume":"18","author":"DM Jiang","year":"2021","unstructured":"Jiang, D. M. et al. Defining cisplatin eligibility in patients with muscle-invasive bladder cancer. Nat. Rev. Urol. 18, 104\u2013114 (2021).","journal-title":"Nat. Rev. Urol."},{"key":"1211_CR7","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1200\/JCO.18.01148","volume":"36","author":"A Necchi","year":"2018","unstructured":"Necchi, A. et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): an open-label, single-arm, phase II study. J. Clin. Oncol. 36, 3353\u20133360 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR8","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","volume":"25","author":"T Powles","year":"2019","unstructured":"Powles, T. et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat. Med. 25, 1706\u20131714 (2019).","journal-title":"Nat. Med."},{"key":"1211_CR9","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1200\/JCO.2020.38.6_suppl.439","volume":"38","author":"S Gupta","year":"2020","unstructured":"Gupta, S. et al. Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle-invasive bladder cancer (MIBC) undergoing cystectomy. J. Clin. Oncol. 38, 439\u2013439 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR10","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1200\/JCO.2023.41.6_suppl.448","volume":"41","author":"J Brown","year":"2023","unstructured":"Brown, J. et al. HCRN GU14-188: Phase Ib\/II study of neoadjuvant pembrolizumab and chemotherapy for T2-4aN0M0 urothelial cancer. J. Clin. Oncol. 41, 448\u2013448 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR11","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1038\/s43018-024-00822-0","volume":"5","author":"K Li","year":"2024","unstructured":"Li, K. et al. Neoadjuvant gemcitabine\u2013cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial. Nat. Cancer 5, 1465\u20131478 (2024).","journal-title":"Nat. Cancer"},{"key":"1211_CR12","doi-asserted-by":"publisher","unstructured":"Wei, Y. et al. Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-center\u2019s real-world study. Front. Pharmacol. 14, https:\/\/doi.org\/10.3389\/fphar.2023.1230395 (2023).","DOI":"10.3389\/fphar.2023.1230395"},{"key":"1211_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011881","volume":"13","author":"J Xiao","year":"2025","unstructured":"Xiao, J. et al. Overcoming immunotherapy resistance in bladder cancer with a novel antibody-drug conjugate RC48. J. Immunother. Cancer 13, e011881 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"1211_CR14","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/s41419-023-06073-8","volume":"14","author":"X Wu","year":"2023","unstructured":"Wu, X. et al. A HER2-targeting antibody-MMAE conjugate RC48 sensitizes immunotherapy in HER2-positive colon cancer by triggering the cGAS-STING pathway. Cell Death Dis. 14, 550 (2023).","journal-title":"Cell Death Dis."},{"key":"1211_CR15","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1200\/JCO.22.02912","volume":"42","author":"X Sheng","year":"2024","unstructured":"Sheng, X. et al. Efficacy and safety of disitamab vedotin in patients with human epidermal growth factor receptor 2-positive locally advanced or metastatic urothelial carcinoma: a combined analysis of two phase II clinical trials. J. Clin. Oncol. 42, 1391\u20131402 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR16","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.annonc.2024.12.002","volume":"36","author":"L Zhou","year":"2025","unstructured":"Zhou, L. et al. Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib\/II dose-escalation and dose-expansion study. Ann. Oncol. 36, 331\u2013339 (2025).","journal-title":"Ann. Oncol."},{"key":"1211_CR17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511648","author":"X Sheng","year":"2025","unstructured":"Sheng, X. et al. Disitamab vedotin plus toripalimab in HER2-expressing advanced urothelial cancer. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2511648 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1211_CR18","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.1200\/JCO.2024.42.16_suppl.4568","volume":"42","author":"X Sheng","year":"2024","unstructured":"Sheng, X. et al. Preliminary efficacy and safety results from RC48-C017: a phase II study of neoadjuvant treatment with disitamab vedotin plus toripalimab in patients with muscle-invasive bladder cancer (MIBC) with HER2 expression. J. Clin. Oncol. 42, 4568\u20134568 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR19","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1200\/JCO.2025.43.5_suppl.665","volume":"43","author":"X Sheng","year":"2025","unstructured":"Sheng, X. et al. Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with muscle-invasive bladder cancer (MIBC) with HER2 expression: Updated efficacy and safety results from the phase II RC48-C017 trial. J. Clin. Oncol. 43, 665\u2013665 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR20","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.eururo.2022.07.002","volume":"82","author":"GJ Netto","year":"2022","unstructured":"Netto, G. J. et al. The 2022 World Health Organization classification of tumors of the urinary system and male genital organs\u2014Part B: prostate and urinary tract tumors. Eur. Urol. 82, 469\u2013482 (2022).","journal-title":"Eur. Urol."},{"key":"1211_CR21","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1200\/JCO.21.01485","volume":"40","author":"SA Funt","year":"2022","unstructured":"Funt, S. A. et al. Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: a multicenter, single-arm, phase II trial. J. Clin. Oncol. 40, 1312\u20131322 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR22","doi-asserted-by":"publisher","first-page":"4595","DOI":"10.1200\/JCO.2023.41.16_suppl.4595","volume":"41","author":"TW Flaig","year":"2023","unstructured":"Flaig, T. W. et al. Study EV-103: neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients (pts) with muscle invasive bladder cancer (MIBC): Updated results for Cohort H. J. Clin. Oncol. 41, 4595\u20134595 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR23","doi-asserted-by":"publisher","first-page":"TPS585","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS585","volume":"41","author":"A Necchi","year":"2023","unstructured":"Necchi, A. et al. Phase 3 KEYNOTE-905\/EV-303: Perioperative pembrolizumab (pembro) or pembro + enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC). J. Clin. Oncol. 41, TPS585\u2013TPS585 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR24","doi-asserted-by":"publisher","unstructured":"Vulsteke, C. et al. in Annals of Oncology 36 S1-S60. https:\/\/doi.org\/10.1016\/annonc\/annonc1965 (2025).","DOI":"10.1016\/annonc\/annonc1965"},{"key":"1211_CR25","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1097\/JS9.0000000000000859","volume":"110","author":"SW Kim","year":"2024","unstructured":"Kim, S. W. et al. HER2 overexpression predicts pathological T2 stage and improved survival in de novo muscle-invasive bladder cancer after immediate radical cystectomy: a retrospective cohort study. Int. J. Surg. 110, 847\u2013858 (2024).","journal-title":"Int. J. Surg."},{"key":"1211_CR26","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s11255-007-9283-x","volume":"40","author":"SB Kolla","year":"2008","unstructured":"Kolla, S. B. et al. Prognostic significance of Her2\/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy. Int. Urol. Nephrol. 40, 321\u2013327 (2008).","journal-title":"Int. Urol. Nephrol."},{"key":"1211_CR27","first-page":"2440","volume":"7","author":"RE Jimenez","year":"2001","unstructured":"Jimenez, R. E. et al. Her-2\/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin. Cancer Res. 7, 2440\u20132447 (2001).","journal-title":"Clin. Cancer Res."},{"key":"1211_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-025-01075-x","author":"D Raggi","year":"2025","unstructured":"Raggi, D. et al. HER2 and urothelial carcinoma: current understanding and future directions. Nat. Rev. Urol. https:\/\/doi.org\/10.1038\/s41585-025-01075-x (2025).","journal-title":"Nat. Rev. Urol."},{"key":"1211_CR29","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.euo.2023.02.008","volume":"6","author":"E Grobet-Jeandin","year":"2023","unstructured":"Grobet-Jeandin, E. et al. A systematic review of oncological outcomes associated with bladder-sparing strategies in patients achieving complete clinical response to initial systemic treatment for localized muscle-invasive bladder cancer. Eur. Urol. Oncol. 6, 251\u2013262 (2023).","journal-title":"Eur. Urol. Oncol."},{"key":"1211_CR30","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1038\/s41591-023-02568-1","volume":"29","author":"MD Galsky","year":"2023","unstructured":"Galsky, M. D. et al. Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial. Nat. Med. 29, 2825\u20132834 (2023).","journal-title":"Nat. Med."},{"key":"1211_CR31","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1200\/JCO.2006.08.0994","volume":"25","author":"MH Hussain","year":"2007","unstructured":"Hussain, M. H. et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2\/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J. Clin. Oncol. 25, 2218\u20132224 (2007).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR32","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1200\/JCO.2015.66.3468","volume":"35","author":"T Powles","year":"2017","unstructured":"Powles, T. et al. Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1\/2-positive metastatic bladder cancer. J. Clin. Oncol. 35, 48\u201355 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR33","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff, A. C. et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. J. Clin. Oncol. 31, 3997\u20134013 (2013).","journal-title":"J. Clin. Oncol."},{"key":"1211_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-020-0901-4","volume":"22","author":"H Zhang","year":"2020","unstructured":"Zhang, H., Moisini, I., Ajabnoor, R. M., Turner, B. M. & Hicks, D. G. Applying the new guidelines of HER2 testing in breast cancer. Curr. Oncol. Rep. 22, 51 (2020).","journal-title":"Curr. Oncol. Rep."},{"key":"1211_CR35","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1111\/j.1464-410X.2005.05452.x","volume":"95","author":"T G\u00e5rdmark","year":"2005","unstructured":"G\u00e5rdmark, T., Wester, K., De La Torre, M., Carlsson, J. & Malmstr\u00f6m, P.-U. Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. BJU Int. 95, 982\u2013986 (2005).","journal-title":"BJU Int."},{"key":"1211_CR36","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","volume":"27","author":"X Sheng","year":"2021","unstructured":"Sheng, X. et al. Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody\u2013drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma. Clin. Cancer Res. 27, 43\u201351 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1211_CR37","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1002\/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C","volume":"73","author":"AM Mandard","year":"1994","unstructured":"Mandard, A. M. et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 73, 2680\u20132686 (1994).","journal-title":"Cancer"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01211-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01211-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01211-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T14:50:15Z","timestamp":1767797415000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01211-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1211"],"URL":"https:\/\/doi.org\/10.1038\/s41698-025-01211-1","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11"}}